Research ArticleNeuropharmacology
Pharmacokinetic-Pharmacodynamic Modeling of Brain Dopamine Levels Based on Dopamine Transporter Occupancy after Administration of Methylphenidate in Rats
Ryosuke Shimizu, Naotaka Horiguchi, Koji Yano, Masashi Sakuramoto, Naoki Kanegawa, Shunji Shinohara and Shuichi Ohnishi
Journal of Pharmacology and Experimental Therapeutics April 2019, 369 (1) 78-87; DOI: https://doi.org/10.1124/jpet.118.252262
Ryosuke Shimizu
Clinical Pharmacology and Pharmacokinetics (R.S.), Neuroscience Drug Discovery and Disease Research Laboratory (N.H., K.Y.), and Drug Metabolism and Pharmacokinetics (M.S., N.K., S.O.), Shionogi & Co., Ltd., Osaka, Japan; and Technology for Animal Models, Shionogi TechnoAdvance Research Co., Ltd., Osaka, Japan (S.S.)
Naotaka Horiguchi
Clinical Pharmacology and Pharmacokinetics (R.S.), Neuroscience Drug Discovery and Disease Research Laboratory (N.H., K.Y.), and Drug Metabolism and Pharmacokinetics (M.S., N.K., S.O.), Shionogi & Co., Ltd., Osaka, Japan; and Technology for Animal Models, Shionogi TechnoAdvance Research Co., Ltd., Osaka, Japan (S.S.)
Koji Yano
Clinical Pharmacology and Pharmacokinetics (R.S.), Neuroscience Drug Discovery and Disease Research Laboratory (N.H., K.Y.), and Drug Metabolism and Pharmacokinetics (M.S., N.K., S.O.), Shionogi & Co., Ltd., Osaka, Japan; and Technology for Animal Models, Shionogi TechnoAdvance Research Co., Ltd., Osaka, Japan (S.S.)
Masashi Sakuramoto
Clinical Pharmacology and Pharmacokinetics (R.S.), Neuroscience Drug Discovery and Disease Research Laboratory (N.H., K.Y.), and Drug Metabolism and Pharmacokinetics (M.S., N.K., S.O.), Shionogi & Co., Ltd., Osaka, Japan; and Technology for Animal Models, Shionogi TechnoAdvance Research Co., Ltd., Osaka, Japan (S.S.)
Naoki Kanegawa
Clinical Pharmacology and Pharmacokinetics (R.S.), Neuroscience Drug Discovery and Disease Research Laboratory (N.H., K.Y.), and Drug Metabolism and Pharmacokinetics (M.S., N.K., S.O.), Shionogi & Co., Ltd., Osaka, Japan; and Technology for Animal Models, Shionogi TechnoAdvance Research Co., Ltd., Osaka, Japan (S.S.)
Shunji Shinohara
Clinical Pharmacology and Pharmacokinetics (R.S.), Neuroscience Drug Discovery and Disease Research Laboratory (N.H., K.Y.), and Drug Metabolism and Pharmacokinetics (M.S., N.K., S.O.), Shionogi & Co., Ltd., Osaka, Japan; and Technology for Animal Models, Shionogi TechnoAdvance Research Co., Ltd., Osaka, Japan (S.S.)
Shuichi Ohnishi
Clinical Pharmacology and Pharmacokinetics (R.S.), Neuroscience Drug Discovery and Disease Research Laboratory (N.H., K.Y.), and Drug Metabolism and Pharmacokinetics (M.S., N.K., S.O.), Shionogi & Co., Ltd., Osaka, Japan; and Technology for Animal Models, Shionogi TechnoAdvance Research Co., Ltd., Osaka, Japan (S.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleNeuropharmacology
Dopamine PK-PD Model of Methylphenidate
Ryosuke Shimizu, Naotaka Horiguchi, Koji Yano, Masashi Sakuramoto, Naoki Kanegawa, Shunji Shinohara and Shuichi Ohnishi
Journal of Pharmacology and Experimental Therapeutics April 1, 2019, 369 (1) 78-87; DOI: https://doi.org/10.1124/jpet.118.252262
Research ArticleNeuropharmacology
Dopamine PK-PD Model of Methylphenidate
Ryosuke Shimizu, Naotaka Horiguchi, Koji Yano, Masashi Sakuramoto, Naoki Kanegawa, Shunji Shinohara and Shuichi Ohnishi
Journal of Pharmacology and Experimental Therapeutics April 1, 2019, 369 (1) 78-87; DOI: https://doi.org/10.1124/jpet.118.252262
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement